The Chicago Corporation provides corporate finance services including merger and acquisition, capital raising and other financial advice to the owners, CEO's and directors of middle-market public and private companies.
The firms investment bankers and senior advisors have hundreds of years of corporate finance advisory experience and extensive management backgrounds in a broad array of industries.
The firm also offers Wealth Transition and Strategic Advisory services which facilitates an owners ability to build a business to a valuation congruent with longer term family goals and objectives often without the need for an interim transaction.
Whether your needs as a business owner require professional execution of a defined need or in-depth consultation about how to maximize both valuation and liquidity objectives, the professionals at The Chicago Corporation have the know-how and experience to help achieve your objectives.
For a brief summary of the Chicago Corporation click here. RECENT NEWS - to sign up for news alerts click here Securities transactions conducted through TCC Securities LLC, member FINRA /SIPC.
312.283.0825 135 South LaSalle St., Suite 2130 Chicago, Illinois 60603
The Chicago Corporation - copyright 2011
The Chicago Corporation is a middle-market investment banking firm, headquartered in Chicago, IL, that strives to provide best-in-class investment banking advice to its clients.
For The Chicago Corporation newsletters click here. For insights and observations on subjects that are important to owners of middle market companies see the "For What It's Worth" section or click here. News release - The Chicago Corporation acted as financial advisor to Bridgeview Bancorp Inc. News release - The Chicago Corporation acted as financial advisor to Smile Doctors, LLC News release - The Chicago Corporation acted as financial advisor to Holton Food Products News release - The Chicago Corporation acted as financial advisor to Manor Resources, LLC News release - Dale Gerding, MD, has retained The Chicago Corporation to assist him in finding an exclusive licensee for his patented technology for the prevention and treatment of Clostridium difficile infection.